stockrow
Friday 6 November 2026
Export LGVN’s income statement to Excel — free account
Longeveron Inc.
LGVN Healthcare Biotechnology
Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024.
- Revenue
- −9.18%
- EPS
- +42.4%
- Free cash flow
- −49.1%
Quarter to June 2026, against a year earlier
1.79
0.08
+4.68%
Follow LGVN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 3 | 4 |
+8 more TTM periods Free account |
| (203.61%) | (135.18%) | (164.75%) | (119.93%) | ||
| (145.64%) | (106.66%) | (126.77%) | (93.89%) | ||
ROIC |
(4,549.04%) | (1,365.87%) | (1,230.29%) | (1,919.23%) | |
Return on Tangible Assets |
(272.38%) | (158.39%) | (709.50%) | (283.74%) | |
Average Days of Receivables |
19.99 | 20.41 | 31.66 | 13.21 | |
Free Cash Flow per Share |
(6.64) | (7.49) | (10.95) | (9.46) | |
Free Cash Flow |
(20.84) | (18.56) | (19.24) | (17.38) | |
Capital Expenditures |
(0.47) | (0.25) | (0.59) | (0.65) | |
| Other line items | |||||
Cash ROIC |
(101.76%) | (57.01%) | (183.15%) | (90.45%) | |
Accounts Receivable Turnover |
24.73 | 25.07 | 12.76 | 6.65 | |
Accounts Payable Turnover |
0.54 | 1.28 | 1.52 | 0.37 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
643.58 | 252.23 | 389.89 | 1,088.95 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,018.11% | 974.10% | 1,004.25% | 787.13% | |
Selling, General and Administrative Expense of Revenue |
1,044.48% | 972.70% | 1,004.92% | 830.55% | |
Share Based Compensation of Revenue |
132.77% | 141.12% | 139.87% | 117.68% | |
Operating CF/Net income |
0.87 | 0.82 | 0.82 | 0.78 | |
Depreciation/Fixed assets |
0.63 | 0.64 | 0.67 | 0.56 | |
Capex/Depreciation |
(0.46) | (0.23) | (0.49) | (0.55) | |
Revenue per Share |
0.38 | 0.49 | 0.68 | 0.78 | |
Operating CF per Share |
(6.49) | (7.39) | (10.61) | (9.10) | |
Capex per Share |
(0.15) | (0.10) | (0.34) | (0.36) | |
Capex to Sales |
0.39 | 0.20 | 0.50 | 0.46 |
Columns are period end dates · fundamentals updated 26 Oct 2026